发布求助
文献互助 智能选刊 最新文献

Clinical Immunology Communications最新文献

筛选
英文 中文
Immune microenvironment and progress in immunotherapy of cholangiocarcinoma 胆管癌免疫微环境及免疫治疗进展
Clinical Immunology Communications Pub Date : 2023-11-29 DOI: 10.1016/j.clicom.2023.11.002
Xinyu Shao
{"title":"Immune microenvironment and progress in immunotherapy of cholangiocarcinoma","authors":"Xinyu Shao","doi":"10.1016/j.clicom.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.11.002","url":null,"abstract":"<div><p>Cholangiocarcinoma (CCA) is a group of malignant digestive system tumors with a poor overall prognosis. Late diagnosis and limited treatment are the main problems of CCA. Immunotherapy is a promising method to improve the prognosis, but the immunosuppression of CCA tumor microenvironment hinders the development and implementation of immunotherapy. Therefore, a full understanding of the complex components of CCA and its tumor immune microenvironment (TiME) can better understand the pathogenesis and drug resistance mechanism of CCA and contribute to the discovery of new immunotherapy targets. This article reviews the TiME related research on CCA, comprehensively discusses the components of the immune microenvironment of cholangiocarcinoma, and introduces the research progress of immunotherapy and immune combination therapy for CCA.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 73-78"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277261342300029X/pdfft?md5=96a4cfb37b3b9075b3279e4257bd499c&pid=1-s2.0-S277261342300029X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138475163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TBE-antibody titer study: Is a booster already necessary after 5 years? tbe抗体滴度研究:5年后是否需要加强?
Clinical Immunology Communications Pub Date : 2023-11-09 DOI: 10.1016/j.clicom.2023.11.001
Katharina Mahlfleisch, Susanne Pauschenwein, Thomas Pekar
{"title":"TBE-antibody titer study: Is a booster already necessary after 5 years?","authors":"Katharina Mahlfleisch,&nbsp;Susanne Pauschenwein,&nbsp;Thomas Pekar","doi":"10.1016/j.clicom.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.11.001","url":null,"abstract":"<div><p>As long as there is only symptomatic treatment against thick-borne encephalitis (TBE) available, vaccination is considered the only prevention against infection.</p><p>The national vaccination recommendations prescribe a booster vaccination every 5 years after a basic vaccination has been carried out. This study deals with the question if antibodies in sufficient concentration exist or not when the last immunization had been five years ago.</p><p>The TBE titer was determined in 168 subjects using indirect ELISA and the vaccination history was collected.</p><p>The results show that 97.3 % of the participants have a sufficient titer 5 years after the last booster vaccination. The time period since the last booster and the type of the vaccine influence the antibody level the most. In conclusion, it was found that by controlling the titer, it is possible to postpone a booster vaccination, if the immunization is still sufficient.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 70-72"},"PeriodicalIF":0.0,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613423000288/pdfft?md5=b6c5501b117cf506020a828a1da6f044&pid=1-s2.0-S2772613423000288-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92116947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in the diagnosis and management of SLE in India 印度SLE诊断和管理的挑战
Clinical Immunology Communications Pub Date : 2023-10-18 DOI: 10.1016/j.clicom.2023.10.001
Rudrarpan Chatterjee, Amita Aggarwal
{"title":"Challenges in the diagnosis and management of SLE in India","authors":"Rudrarpan Chatterjee,&nbsp;Amita Aggarwal","doi":"10.1016/j.clicom.2023.10.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.10.001","url":null,"abstract":"<div><p>Management of Systemic lupus erythematosus is challenging due to its varied manifestations, relapses and problems associated with immunosuppressive therapy. This challenge is compounded in resource limited countries due to additional factors such as poor access to health care, limited income, out of pocket expenses for medical care and lack of financial independence of women. In the current review some of these issues have been highlighted in context of India, the most populous country of the world with current annual per capita income of around 2000 dollars.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 65-69"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613423000276/pdfft?md5=29c6a1975841e985cf4103be77469c87&pid=1-s2.0-S2772613423000276-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92149049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic lupus erythematosus in Latin America: Outcomes and therapeutic challenges 拉丁美洲的系统性红斑狼疮:结果和治疗挑战
Clinical Immunology Communications Pub Date : 2023-10-17 DOI: 10.1016/j.clicom.2023.10.002
Manuel F. Ugarte-Gil , Graciela S. Alarcón
{"title":"Systemic lupus erythematosus in Latin America: Outcomes and therapeutic challenges","authors":"Manuel F. Ugarte-Gil ,&nbsp;Graciela S. Alarcón","doi":"10.1016/j.clicom.2023.10.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.10.002","url":null,"abstract":"<div><p>Systemic lupus erythematosus (SLE) affects more severely non-White populations, which is also the case in Latin America; this is the result of a combination of genetic and non-genetic factors. Among the non-genetic factors, a limited income and a low educational level impact negatively on the course and outcome of the disease; in addition, lack of access to healthcare services deprives patients from the opportunity of being managed by specialists, making the availability of the newest drugs practically impossible. Taking together, these factors reduce the probability of patients achieving good outcomes, like remission, less damage accrual, a better survival and a better health-related quality of life, among others. Several strategies have been proposed to reduce these disparities, including peer education, educational activities for patients and primary care physicians, improving healthcare networks and generating cost-effectiveness analyses.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 60-64"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49727533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disseminated tuberculosis, CMV viraemia & haemophagocytic-lymphohistiocystosis syndrome in an adult patient with anti- IFNγ autoantibodies – case report and brief review 成人抗IFNγ自身抗体患者的弥散性结核、巨细胞病毒血症和噬血细胞淋巴组织囊积综合征——病例报告和简要回顾
Clinical Immunology Communications Pub Date : 2023-09-01 DOI: 10.1016/j.clicom.2023.08.001
G.I. Butel-Simoes , C. Kiss , K. Kong , L.B. Rosen , L.M. Hosking , S. Barnes , G.A. Jenkin , S. Megaloudis , B. Kumar , S.M. Holland , S. Ojaimi
{"title":"Disseminated tuberculosis, CMV viraemia & haemophagocytic-lymphohistiocystosis syndrome in an adult patient with anti- IFNγ autoantibodies – case report and brief review","authors":"G.I. Butel-Simoes ,&nbsp;C. Kiss ,&nbsp;K. Kong ,&nbsp;L.B. Rosen ,&nbsp;L.M. Hosking ,&nbsp;S. Barnes ,&nbsp;G.A. Jenkin ,&nbsp;S. Megaloudis ,&nbsp;B. Kumar ,&nbsp;S.M. Holland ,&nbsp;S. Ojaimi","doi":"10.1016/j.clicom.2023.08.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.08.001","url":null,"abstract":"<div><p>We report a case of an adult female with disseminated tuberculosis, cytomegalovirus viraemia and haemophagocytic-lymphohistiocystosis syndrome associated with neutralizing anti- interferon gamma (IFNγ) autoantibodies demonstrated by absent IFNγ stimulated STAT1 phosphorylation in the presence of patient sera. A brief review of immunodeficiency caused by anti-IFNγ autoantibodies is also described.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 55-59"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-series COVID-19 policy outcome analysis of the 50U.S. states 美国50个州COVID-19政策结果的时序分析。州
Clinical Immunology Communications Pub Date : 2023-08-23 DOI: 10.1016/j.clicom.2023.08.002
Yoshiyasu Takefuji , Junya Toyokura
{"title":"Time-series COVID-19 policy outcome analysis of the 50U.S. states","authors":"Yoshiyasu Takefuji ,&nbsp;Junya Toyokura","doi":"10.1016/j.clicom.2023.08.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.08.002","url":null,"abstract":"<div><p>Goal of health policies is to protect and promote the health of communities. We examined COVID-19 policy outcomes of the 50 US states according to policymaker assumptions over time. With daily cumulative population mortality chosen as an indicator to evaluate and score outcomes of individual health policies, Hawaii had the best score and Arizona has the worst score. Our policy outcome analysis tool could identify and quantify policymakers’ faulty assumptions against COVID-19, and concludes that the more COVID-19 deaths, the greater the economic loss.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 51-54"},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel approaches that promote lung endothelial and epithelial repair and anti pro inflammatory cytokines could be a future promising agent in the management of ARDS 促进肺内皮和上皮修复和抗促炎细胞因子的新方法可能是未来治疗ARDS的有希望的药物
Clinical Immunology Communications Pub Date : 2023-07-28 DOI: 10.1016/j.clicom.2023.07.005
Montaser Alrjoob , Alaa Alkhatib , Rana Padappayil , Husam Bader , Doantrang Du , Chandler Patton
{"title":"Novel approaches that promote lung endothelial and epithelial repair and anti pro inflammatory cytokines could be a future promising agent in the management of ARDS","authors":"Montaser Alrjoob ,&nbsp;Alaa Alkhatib ,&nbsp;Rana Padappayil ,&nbsp;Husam Bader ,&nbsp;Doantrang Du ,&nbsp;Chandler Patton","doi":"10.1016/j.clicom.2023.07.005","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.005","url":null,"abstract":"<div><p>The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is defined by the acute onset of noncardiogenic pulmonary edema, hypoxemia, and the need for mechanical ventilation. ARDS occurs most often in the setting of pneumonia, sepsis, aspiration of gastric contents or severe trauma, and is present in ∼10% of all intensive care unit patients worldwide. Pathologic specimens from patients with ARDS most frequently reveal diffuse alveolar damage, and laboratory studies have demonstrated both alveolar epithelial and lung endothelial injury, resulting in accumulation of protein-rich inflammatory edema fluid in the alveolar space. The current therapeutic regimen is comprised of supportive measures such as lung protective ventilation, restrictive fluid management, paralyzing drugs, and prone positioning. Although vast improvements have been made in ARDS-treatment during the last five decades, mortality among patients with severe ARDS remains at an unacceptable rate of 45%.This article reviews the evolution of the currently used definition, established pathophysiological mechanism, highlights the current best clinical practice to treat ARDS, gives a brief outlook on cutting edge trends in ARDS research and closes with an expert opinion on the subject. The ongoing digital revolution will help to individualize ARDS-treatment and will therefore presumably improve survival and quality of life.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 45-50"},"PeriodicalIF":0.0,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study 中老年个体血清免疫球蛋白水平和抗生素处方风险:一项基于人群的队列研究
Clinical Immunology Communications Pub Date : 2023-07-22 DOI: 10.1016/j.clicom.2023.07.003
Anna Vanoverschelde , Samer R. Khan , Virgil A.S.H. Dalm , Layal Chaker , Guy Brusselle , Bruno H. Stricker , Lies Lahousse
{"title":"Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study","authors":"Anna Vanoverschelde ,&nbsp;Samer R. Khan ,&nbsp;Virgil A.S.H. Dalm ,&nbsp;Layal Chaker ,&nbsp;Guy Brusselle ,&nbsp;Bruno H. Stricker ,&nbsp;Lies Lahousse","doi":"10.1016/j.clicom.2023.07.003","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.003","url":null,"abstract":"<div><h3>Objectives</h3><p>Elderly become more susceptible to lower respiratory tract infections, resulting in antibiotic prescriptions. Immunoglobulins (Ig) play an important role in host defense and protection against infections. Therefore, we aimed to investigate whether lower Ig levels are a risk factor for antibiotic use in the general elderly population.</p></div><div><h3>Methods</h3><p>After exclusion of current antibiotic users, Cox proportional-hazards regression models were performed to investigate the effect of stable serum IgM, IgG and IgA levels on time to first antibiotic prescription within the Rotterdam Study. Regression models were adjusted for age, sex, body mass index, smoking status and diabetes. We introduced quadratic terms and additionally categorized Igs to explore and quantify potential non-linearity of the association. The restricted cubic splines technique was used to plot the natural log of the hazard across Ig level.</p></div><div><h3>Results</h3><p>In total, 8,639 participants were included (mean age 64 years, 57% female, medium follow-up 3.2 years). No significant association between IgM and time to antibiotic prescription was observed. IgG and IgA levels (in g/L) showed a U-shaped relationship with time to antibiotic prescription (linear IgG HR 0.959, 95% CI 0.930–0.989; quadratic IgG² HR 1.002, 95% CI 1.000–1.003; linear IgA HR 0.949, 95% CI 0.910–0.990; quadratic IgA² HR 1.009, 95% CI 1.004–1.013).</p></div><div><h3>Conclusion</h3><p>Both low and high IgG and IgA levels were associated with a higher incidence of antibiotic prescriptions in stable middle-aged and older individuals. Increased awareness for the potential increased infection risk when persons have low or high Ig levels, even within the reference ranges, is needed.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 23-29"},"PeriodicalIF":0.0,"publicationDate":"2023-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49752593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 2: Sézary syndrome 有色皮肤患者皮肤t细胞淋巴瘤的免疫发病机制。第二部分:ssamzary综合征
Clinical Immunology Communications Pub Date : 2023-07-22 DOI: 10.1016/j.clicom.2023.07.002
Nina C. Nwade , Sachi I. Desse , Akanksha Nagarkar , Nia E.R. James , Ryan Svoboda , Ginette A. Okoye , Jillian M. Richmond , Angel S. Byrd
{"title":"Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 2: Sézary syndrome","authors":"Nina C. Nwade ,&nbsp;Sachi I. Desse ,&nbsp;Akanksha Nagarkar ,&nbsp;Nia E.R. James ,&nbsp;Ryan Svoboda ,&nbsp;Ginette A. Okoye ,&nbsp;Jillian M. Richmond ,&nbsp;Angel S. Byrd","doi":"10.1016/j.clicom.2023.07.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.002","url":null,"abstract":"<div><p>Cutaneous T-cell lymphoma (CTCL) serves as an umbrella term for numerous lymphomas that reside in or recirculate through the skin. One such systemic lymphoma is Sézary Syndrome (SS). Although SS is not as common in Skin of Color (SOC), minority patients presenting with the condition do have a different presentation than their White counterparts. In this graphical review, we provide an overview of SS immunopathogenesis and varying presentations. Additionally, a summary of current treatment options is provided, highlighting ongoing clinical trials and opportunities to include SOC patients to promote health equity. SOC patients often have poorer prognosis due to biological differences and health disparities resulting in delayed diagnosis. This exemplifies the potential advantages and promising solutions of precision medicine implementation. To this end, the impact and benefits of precision medicine are summarized.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 30-34"},"PeriodicalIF":0.0,"publicationDate":"2023-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49752599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 1: Mycosis fungoides 有色皮肤患者皮肤t细胞淋巴瘤的免疫发病机制第一部分:蕈样真菌病
Clinical Immunology Communications Pub Date : 2023-07-20 DOI: 10.1016/j.clicom.2023.07.004
Sachi I. Desse , Nina C. Nwade , Akanksha Nagarkar , Nia E.R. James , Ryan Svoboda , Ginette A. Okoye , Angel S. Byrd , Jillian M. Richmond
{"title":"Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 1: Mycosis fungoides","authors":"Sachi I. Desse ,&nbsp;Nina C. Nwade ,&nbsp;Akanksha Nagarkar ,&nbsp;Nia E.R. James ,&nbsp;Ryan Svoboda ,&nbsp;Ginette A. Okoye ,&nbsp;Angel S. Byrd ,&nbsp;Jillian M. Richmond","doi":"10.1016/j.clicom.2023.07.004","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.004","url":null,"abstract":"<div><p>Mycosis fungoides (MF) is the most common subtype of Cutaneous T-Cell Lymphoma (CTCL). Patients with Skin of Color (SOC) may be disproportionately impacted by MF due to delayed diagnoses, limited research, and treatment differences. In this graphical review, we provide an overview of MF immunopathogenesis and demonstrate how it manifests differently in SOC patients. We also provide our hypothesis for why the disease process can result in a myriad of clinical presentations in SOC patients. Last, we provide a summary of current treatment options, highlighting ongoing clinical trials and opportunities to include SOC patients to promote health equity.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":"4 ","pages":"Pages 35-40"},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49727364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信